DGAP-News: Ekso Bionics(R) to Establish Headquarters in

DGAP-News: Ekso Bionics Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany; Strengthens European Expansion Efforts 12.11.2015 / 13:00 --------------------------------------------------------------------- Freiburg-Based Headquarters to Provide Enhanced Support and Services to Developing Markets RICHMOND, Calif., 2015-11-12 13:00 CET (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced today that it has established a new regional headquarters, based in Freiburg, Germany, to further strengthen its European presence and better serve German-speaking markets. The expansion is being led by Ruediger Hausherr, President, EMEA, Ekso Bionics, and marks an integral step in the company's development of its Europe, Middle East, and Africa (EMEA) business. 'Establishing this Germany-based subsidiary will allow us to enhance our customer service with training, education, and field service support by being in closer proximity to our valued customers,' said Hausherr. 'The Freiburg headquarters will also position Ekso to build strategic partnerships in the area.' This new site further supports Ekso Bionics' European operations by facilitating regional growth plans, establishing a dedicated sales and customer service organization to more closely liaise with leading rehabilitation centers in the region including existing customers such as Swiss Paraplegic Centre (SPC), Uppsala University Hospital, Sunnaas Hospital, BG Clinics and Schon Klinik Bad Aibling to name a few. 'We are excited to further expand our European business to meet a rise in demand for our advanced technology,' said Thomas Looby, President and Chief Commercial Officer of Ekso Bionics. 'I am pleased to see how Ruediger and the EMEA team have strengthened our business since he joined us in early October. Our presence in Western Europe is a strategic part of our market development and demonstrates our commitment to operational excellence.' About Ekso Bionics Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. www.eksobionics.com Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements. CONTACT: Media Contact: Heidi Darling, Director of Marketing Communications Phone: 510-984-1761 x317 E-mail: hdarling@eksobionics.com Investor Contact: Chad Rubin, Senior Vice President Phone: 646-378-2947 E-mail: crubin@troutgroup.com News Source: NASDAQ OMX --------------------------------------------------------------------- 12.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Ekso Bionics United States End of News DGAP News Service --------------------------------------------------------------------- 412397 12.11.2015